Search Result

Results for "

aggregation inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (5) ADC Cytotoxin (2) Adenosine Receptor (3) Adenylate Cyclase (1) Adrenergic Receptor (2) AMPK (1) Amyloid-β (68) Apoptosis (28) Autophagy (6) Bacterial (5) Beta-secretase (5) Biochemical Assay Reagents (3) Calcium Channel (9) Calmodulin (1) Caspase (2) Cathepsin (1) Cholinesterase (ChE) (51) COMT (1) COX (13) Cytochrome P450 (5) Dengue virus (1) DNA/RNA Synthesis (2) Dopamine Receptor (3) Drug Metabolite (2) DYRK (5) Endogenous Metabolite (25) Estrogen Receptor/ERR (3) Factor Xa (1) Ferroptosis (2) Flavivirus (1) Fungal (4) GABA Receptor (1) Glycoprotein VI (2) GSK-3 (3) Guanylate Cyclase (5) HDAC (3) Histamine Receptor (3) HIV (1) HSP (3) iGluR (2) Influenza Virus (5) Integrin (12) Interleukin Related (1) Isotope-Labeled Compounds (15) JAK (1) JNK (1) Lipoxygenase (2) LPL Receptor (1) MDM-2/p53 (1) Microtubule/Tubulin (16) Monoamine Oxidase (15) mTOR (1) nAChR (4) NADPH Oxidase (1) NF-κB (7) NO Synthase (9) NOD-like Receptor (NLR) (1) P2Y Receptor (30) p38 MAPK (2) Parasite (5) PGE synthase (2) Phosphodiesterase (PDE) (9) PI3K (1) Platelet-activating Factor Receptor (PAFR) (9) Potassium Channel (1) Prostaglandin Receptor (21) Protease Activated Receptor (PAR) (15) Proteasome (2) Ras (1) Reactive Oxygen Species (2) ROS Kinase (1) SARS-CoV (2) Serotonin Transporter (1) Src (1) STAT (1) Syk (1) TAM Receptor (1) Tau Protein (13) Thrombin (14) TMV (1) TNF Receptor (1) Toll-like Receptor (TLR) (3) Transthyretin (TTR) (2) Tyrosinase (1) VSV (1) α-synuclein (14)
By Research Areas:	Cancer (61) Cardiovascular Disease (188) Endocrinology (11) Infection (23) Inflammation/Immunology (45) Metabolic Disease (19) Neurological Disease (148)
Click Chemistry:	Alkynes (1)

422

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

5(S)15(S)-DiHETE	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
5(S)15(S)-DiHETE is an “activated” intermediate, inhibits platelet aggregation with an IC₅₀ of 1.3 μM. 5(S)15(S)-DiHETE enhances the rate of either LXA4 or LXB4 biosynthesis .

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

α-Synuclein inhibitor 13	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

Kadsutherin G	Others	Cardiovascular Disease
Kadsutherin G (compound 3) is a lignin isolated from Kadsura. Kadsutherin G inhibits adenosine diphosphate (ADP)-induced platelet aggregation by 33.1 % .

cis-N-(4-Hydroxystyryl)benzamide	Others	Cardiovascular Disease
cis-N-(4-Hydroxystyryl)benzamide is a platelet aggregation inhibitor that can be isolated from the chloroform extract of Houttuynia cordata, a traditional Chinese medicine .

Hydromethylthionine dihydrobromide Leukomethylene blue dihydrobromide; LMTM dihydrobromide	Tau Protein	Neurological Disease
Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders .

Nexopamil	Calcium Channel 5-HT Receptor Dopamine Receptor	Cardiovascular Disease
Nexopamil is a calcium antagonist of Ca ²⁺ channel, 5HT₂, 5HT_1A, 5HT_1C and dopamine D₂ receptors. Nexopamil exhibits vasodilatory, cardioprotective, and platelet aggregation inhibiting effects. Nexopamil can be used for researches of stable or unstable angina and possibly of peripheral arterial occlusive disease .

BuChE-IN-8	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .

LETC	α-synuclein	Neurological Disease
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC₅₀ of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .

BuChE-IN-9	Cholinesterase (ChE) Beta-secretase GABA Receptor	Neurological Disease
BuChE-IN-9 (compound 22a) is a potent equine serum-derived BuChE (eqBuChE) inhibitor with an IC₅₀ of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties .

DN5355	Amyloid-β	Neurological Disease
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .

SCH 51866	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC₅₀=70 nM) and PDE5 (IC₅₀=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC₅₀=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension .

YIAD-0205	Amyloid-β	Neurological Disease
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .

hAChE-IN-8	Cholinesterase (ChE) DYRK	Neurological Disease
hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC₅₀=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC₅₀=0.542 μM), and does not inhibit Dyrk1A (IC₅₀>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research .

Platelet aggregation-IN-1	Others	Others
Platelet aggregation-IN-1 (Compound 10e) is an inhibitor for platelet aggregation, that inhibits 100% thrombin-induced platalet aggregation at 50 μM .

BSBM6	Others	Others
BSBM6 is a compound with the activity of inhibiting Aβ aggregation and regulating Aβ aggregation. BSBM6 can be demonstrated to inhibit Aβ aggregation through molecular dynamics simulation and related experiments, reducing soluble oligomers, and providing structural guidance for the design of new aggregation regulating ligands.

Cloricromen hydrochloride Cloricromene hydrochloride	Others	Cardiovascular Disease
Cloricromen (Cloricromene) hydrochloride is a platelet aggregation inhibitor. Cloricromen hydrochloride can inhibit platelet aggregation in man and in experimental thrombosis .

Cloricromen Cloricromene; AD6	Biochemical Assay Reagents	Cardiovascular Disease
Cloricromen (Cloricromene) is a platelet aggregation inhibitor. Cloricromen can inhibit platelet aggregation in man and in experimental thrombosis .

Platelet aggregation-IN-2	Others	Cardiovascular Disease
Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .

Tau-aggregation-IN-3	Tau Protein	Neurological Disease
Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC₅₀=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research .

PI-091	Others	Cardiovascular Disease
PI-091 is a platelet aggregation inhibitor, and can be used for researching platelet aggregation .

Aβ/tau aggregation-IN-3	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

Piperlotine D	Others	Cardiovascular Disease
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC₅₀ of 43.4 μg/mL .

*Aβ1–42 aggregation* inhibitor 1**	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

Tau-aggregation and neuroinflammation-IN-1	Microtubule/Tubulin	Neurological Disease Inflammation/Immunology
Tau-aggregation and neuroinflammation-IN-1 is a potent *tau-aggregation* and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats .

Ifenprodil glucuronide	Others	Cardiovascular Disease
Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction .

Evategrel	Others	Cardiovascular Disease
Evategrel is a platelet aggregation inhibitor .

Tau-aggregation-IN-1	Microtubule/Tubulin Dopamine Receptor	Neurological Disease
Tau-aggregation-IN-1 (Compound D-519) is a tau441 protein aggregation inhibitor with an IC₅₀ of 21 µM. Tau-aggregation-IN-1 is also a dopamine D₂ and D₃ receptor agonist .

Tau protein aggregation-IN-1	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

SCH 38519	Bacterial	Infection
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

CRL42872 free base	Prostaglandin Receptor	Cardiovascular Disease
CRL-42872 free base (compound 30) is an oral platelet aggregation inhibitor. CRL-42872 free base can be used for researching platelet aggregation .

Trifenagrel	Others	Cardiovascular Disease
Trifenagrel is a platelet aggregation inhibitor that inhibits the inducing effects of arachidonic acid (AA) and collagen. The ED₅₀s of trifenagrel for inhibiting AA- and collagen-induced platelet aggregation in guinea pigs were 1.4 mg/kg and 9.4 mg/kg, respectively .

Aβ/tau aggregation-IN-1	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-1 is a potent Aβ_1-42 β-sheets formation and tau aggregation inhibitor. The K_D values of Aβ/tau aggregation-IN-1 with Aβ_1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .

*Aβ1–42 aggregation* inhibitor 2**	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

4-Trifluoromethylsalicylic acid Desacetyl triflusal	Others	Others
4-Trifluoromethylsalicylic acid (Desacetyl triflusal) is a platelet aggregation inhibitor .

Prostaglandin I3 sodium	Others	Cardiovascular Disease
Prostaglandin I3 sodium is an inhibitor of platelet aggregation with vasodilatory effects .

tau/Aβ40 aggregation-IN-1	Tau Protein Amyloid-β Cholinesterase (ChE)	Neurological Disease
tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ₄₀ aggregation inhibitor with IC₅₀s of 1.8 μM and 1.3 μM, respectively .

NQTrp	Tau Protein	Neurological Disease
NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide ( ⁴¹GCWMLY ⁴⁶ within the N-terminus of γD-crystallin) as well as full-length γD-crystallin .

TRV-1387	Tau Protein Amyloid-β	Neurological Disease
TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β .

Orbofiban	Integrin	Cardiovascular Disease
Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.

AY1511	Amyloid-β	Neurological Disease
AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity .

Orbofiban acetate	Integrin	Cardiovascular Disease
Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

Cat. No.	Product Name

HY-L193

PBCRBS Traditional Chinese Medicine Compound Library

1,063 compounds

Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields.

MCE can supply 1,063 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.

HY-L133

Cuproptosis Compound Library

216 compounds

Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".

The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.

Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.

Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.

MCE supplies a unique collection of 216 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cat. No.	Product Name	Type

HY-19948

Leucomethylene blue mesylate 5+ Cited Publications TRx0237 mesylate; Methylene blue leuco base mesylate	Chromogenic Assays
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (K_i of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes .

HY-14536

Methylene Blue

10+ Cited Publications

Basic Blue 9; CI-52015; Methylthioninium chloride

Chromogenic Assays

Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

HY-14536A

Methylene blue (purity≥70%)

Basic Blue 9 (purity≥70%); CI-52015 (purity≥70%); Methylthioninium chloride (purity≥70%)

Chromogenic Assays

Methylene blue (purity≥70%) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue (purity≥70%) is a vasopressor and is often used as a dye in several medical procedures. Methylene blue (purity≥70%) through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue (purity≥70%) is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue (purity≥70%) is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

HY-14536R

Methylene Blue (Standard)

Chromogenic Assays

Methylene Blue (Standard) is the analytical standard of Methylene Blue. This product is intended for research and analytical applications. Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

Cat. No.	Product Name	Type

HY-W012898

Dimethylglyoxime Biacetyl dioxime	Biochemical Assay Reagents
Dimethylglyoxime (Biacetyl dioxime) belongs to the class of oximes and consists of two acetyl groups attached to a nitrogen atom, which in turn is attached to another nitrogen atom through a diimine bond. Dimethylglyoxime is a specific chelator of Ni that inhibits or slows the aggregation of Aβ peptides in vitro .

HY-D1005A22

Poloxamer 338 (F108) PEG-PPG-PEG, 14600 (Averag)	Co-solvents
Poloxamer 338 F108 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 14600. Poloxamer 338 F108 reduces the aggregation of red blood cells, inhibits proliferation of human lymphocyte cell IIBR1. Poloxamer 338 F108 exhibits short-term and subchronic toxicity in rats .

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area

HY-P0314A

Arg-Gly-Asp-Cys TFA	Peptides	Cardiovascular Disease
Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding .

HY-P1741

Fibrinogen-Binding Peptide 1 Publications Verification	Peptides	Cardiovascular Disease
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-125053A

Batifiban TFA	Glycoprotein VI	Cardiovascular Disease
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .

HY-P4908

S-(1,2-Dicarboxyethyl)glutathione	Peptides	Cardiovascular Disease
S-(1,2-Dicarboxyethyl)glutathione is a peptide that inhibits blood coagulation and platelet aggregation .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-P3052

RGDV	Peptides	Cancer
RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect .

HY-P0314

Arg-Gly-Asp-Cys	Peptides	Others
Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.

HY-P3012

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

HY-P5991

K-Casein (106-116),bovine	Peptides	Cardiovascular Disease
K-Casein (106-116),bovine is a peptide that inhibits platelet aggregation and fibrinogen binding, plays an important role in atherosclerosis .

HY-P1702

GR83895	Peptides	Others
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC₅₀= 0.9 μM) .

HY-P1741A

Fibrinogen-Binding Peptide TFA 1 Publications Verification	Peptides	Cardiovascular Disease
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-125053

Batifiban	Integrin	Cardiovascular Disease
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and α₅β₁ .

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P1711

L 366763	Peptides	Cardiovascular Disease
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .

HY-P1263

tcY-NH2 (trans-Cinnamoyl)-YPGKF-NH2	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) is a potent selective PAR4 antagonist peptide. tcY-NH2 inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P1263A

tcY-NH2 TFA 1 Publications Verification (trans-Cinnamoyl)-YPGKF-NH2 TFA	Protease Activated Receptor (PAR)	Metabolic Disease Inflammation/Immunology
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. tcY-NH2 TFA inhibits thrombin- and AY-NH₂-induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology .

HY-P3082

SKF 106760	Peptides	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

HY-P5755

SWELYYPLRANL-NH2	Peptides	Cancer
SWELYYPLRANL-NH2 is an E-cadherin and N-cadherin antagonist. SWELYYPLRANL-NH2 inhibits phage clone binding to E- or N-cad/Fc chimeric protein (IC₅₀: 0.7 and 0.09 μM respectively). SWELYYPLRANL-NH2 inhibits cell aggregation. SWELYYPLRANL-NH2 can be used to promote drug delivery through epithelial and endothelial permeability barriers .

HY-P5755A

SWELYYPLRANL-NH2 TFA	Peptides	Cancer
SWELYYPLRANL-NH2 TFA is an E-cadherin and N-cadherin antagonist. SWELYYPLRANL-NH2 TFA inhibits phage clone binding to E- or N-cad/Fc chimeric protein (IC₅₀: 0.7 and 0.09 μM respectively). SWELYYPLRANL-NH2 TFA inhibits cell aggregation. SWELYYPLRANL-NH2 can be used to promote drug delivery through epithelial and endothelial permeability barriers .

HY-P5875

P4pal10	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .

HY-P5322

Thrombospondin (TSP-1)-derived CD36 binding motif	Peptides	Others
Thrombospondin (TSP-1)-derived CD36 binding motif is a biological active peptide. (This peptide is derived from thrombospondin and represents a binding motif responsible for thrombospondin-CD36 interaction. It is cyclized through a disulfide bond. Thrombospondin is a matrix-bound glycoprotein involved in cancer metastasis, tumor adhesion, and angiogenesis. This peptide has been shown to competitively inhibit platelet aggregation and tumor metastasis.)

HY-105066

Davunetide 1 Publications Verification	Microtubule/Tubulin Amyloid-β	Neurological Disease
Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .

HY-P4832

Acetyl-Tau Peptide (273-284) amide	Amyloid-β	Neurological Disease
Acetyl-Tau Peptide (273-284) amide is an acetylated Tau peptide fragment. Acetyl-Tau Peptide (273-284) amide limits the substantial aggregation of Ac-Aβ(25–35)-NH2 and can be used as an inhibitor of Ac-Aβ(25–35)-NH2. Acetyl-Tau Peptide (273-284) amide can be used as an experimental model to investigate the Aβ/Tau cross-interaction .

HY-P5875A

P4pal10 TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .

Cat. No.	Product Name	Target	Research Area

HY-P99644

Glenzocimab ACT017	Inhibitory Antibodies	Cardiovascular Disease
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke .

HY-P9934

Abciximab C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .

Cat. No.	Product Name	Chemical Structure

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

HY-W777681

Triflusal-13C6
Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor .

HY-B0153AS

Ticlopidine-d4 hydrochloride
Ticlopidine-d₄ (hydrochloride) is the deuterium labeled Ticlopidine hydrochloride. Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.

HY-W014632S

4-Trifluoromethylsalicylic acid-13C6
4-Trifluoromethylsalicylic acid- ¹³C₆ is the ¹³C labeled 4-Trifluoromethylsalicylic acid[1]. 4-Trifluoromethylsalicylic acid is a platelet aggregation inhibitor[2].

HY-W004287S

Methyl tridecanoate-d25
Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE)[1].

HY-Y0882S1

Hydroxylamine-d3 hydrochloride
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-B2158S

Chlorotrianisene-d9
Chlorotrianisene-d₉ is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-17406S

Tolcapone-d7
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran[1]. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[2][3].

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-B0282S

Acetylcholine-d4 chloride

Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S1

Acetylcholine-d9 chloride

Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-10119S

Vorapaxar-d5
Vorapaxar-d₅ is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (K_i=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .

HY-B0523S

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-B0683S

Limaprost-d3
Limaprost-d₃ (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].

HY-B0131S

Prostaglandin E1-d4

Prostaglandin E1-d₄ is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].

HY-W010918S

Adenosine 5'-diphosphate-d13 dilithium

Adenosine 5'-diphosphate-d₁₃ (Adenosine diphosphate-d₁₃ dilithium; ADP-d₁₃) dilithium is deuterium labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors.

HY-W010918S2

Adenosine 5'-diphosphate-15N5 dilithium

Adenosine 5'-diphosphate- ¹⁵N₅ (Adenosine diphosphate- ¹⁵N₅ dilithium; ADP- ¹⁵N₅) dilithium is ¹⁵N labeled Adenosine 5'-diphosphate (HY-W010918). Adenosine 5'-diphosphate (Adenosine diphosphate) is a nucleoside diphosphate. Adenosine 5'-diphosphate is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate induces human platelet aggregation and inhibits stimulated adenylate cyclase by an action at P_2T-purinoceptors.

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Cat. No.	Product Name		Classification

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

aggregation inhibitors

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products